[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MAXVAX Biotechnology Limited Liability Company\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,65,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100638062","a-study-to-evaluate-the-immune-response-features-following-vaccination-with-a-recombinant-respiratory-syncytial-virus-vaccine-cho-cells-100638062",false,"NCT07618325","A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)","Inclusion Criteria:\n\n* Participants must be 20 years of age or older as determined by the investigator at enrollment.\n* Participants must be able to understand study procedures, risks, and benefits, provide voluntary agreement to participate in the study, and sign the informed consent form (ICF).\n* Participants must be willing and able to attend all scheduled follow-up visits and comply with all requirements specified in the study protocol.\n* Females of childbearing potential must use highly effective contraception from 1 month prior to vaccination through 12 months following vaccination.\n\n  * Effective contraceptive methods include: oral contraceptives (excluding emergency contraceptives), contraceptive injections, subcutaneous implants, hormonal patches, intrauterine devices (IUDs), surgical sterilization, true abstinence, and condom use.\n  * Methods not considered effective include: rhythm method, withdrawal method, and emergency contraception.\n\nExclusion Criteria:\n\n\\*Participants who meet any of the following criteria shall be ineligible for enrollment:\n\n* Axillary body temperature ≥ 37.3 °C.\n* History of respiratory syncytial virus (RSV) infection within 6 months prior to enrollment.\n* New-onset respiratory infection symptoms within 7 days prior to enrollment, including cough, expectoration, dyspnea, wheezing, fever, rhinorrhea, and nasal obstruction.\n* Presence of an acute illness or acute exacerbation of a chronic condition within 3 days prior to enrollment.\n* Use of antipyretics and analgesics (excluding enteric-coated aspirin for the prevention of cardiovascular and cerebrovascular diseases) or antiallergic medications within 3 days prior to enrollment.\n* Known hypersensitivity to any ingredient of the study vaccine, including Quillaja saponaria (QS-21), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholesterol, sucrose, sodium dihydrogen phosphate, anhydrous disodium hydrogen phosphate, polysorbate 80, sodium chloride, hydrochloric acid, and sodium hydroxide; history of severe allergic reactions or serious adverse events following any vaccination or drug administration, including anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local Arthus reaction, and severe urticaria.\n* Pregnant female (positive urine pregnancy test), lactating female, or female with a pregnancy plan within 12 months following vaccination.\n* Congenital asplenia, functional asplenia, or splenectomy due to any cause.\n* Previous or current malignant neoplasm, with the exception of clinically cured carcinoma in situ and papillary thyroid carcinoma.\n* Confirmed diagnosis of an autoimmune disease, including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and autoimmune thyroid disease.\n* Confirmed or suspected immunosuppression or immunodeficiency resulting from any cause, including primary or secondary immunocompromise, congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, or treatment with immunosuppressive or cytotoxic agents (e.g., chemotherapy, organ transplantation, or therapy for autoimmune diseases).\n* Any condition that, in the investigator's judgment, would render intramuscular injection unsafe, such as a history of thrombocytopenia or other coagulation disorders.\n* Previous or current serious clinical illness that is not cured (such as serious cardiovascular and cerebrovascular diseases, liver and kidney diseases, respiratory diseases, diabetes with complications, major surgery, etc.) may affect the evaluation of the trial.\n* Previous or current thrombotic diseases.\n* History of untreated tuberculosis or active tuberculosis infection at enrollment.\n* Uncontrolled hypertension defined as systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg on measurement prior to vaccination.\n* History of severe cardiac arrhythmia (e.g., atrial fibrillation).\n* History or family history of convulsions, epilepsy, congenital brain malformation, psychiatric disorders, or other severe neurological conditions associated with cerebral nerve tissue injury, including brain tumor, cerebral hemorrhage, cerebral infarction (excluding lacunar cerebral infarction and cerebral infarction without sequelae), central nervous system infection, and chemical intoxication.\n* History of any cognitive disorder or any moderate or severe condition causing cognitive impairment.\n* Use of any investigational or unlicensed product (medicinal product, vaccine, or medical device) other than the study vaccine within 30 days prior to vaccination, or planned participation in another clinical trial during the study period.\n* Administration of any inactivated vaccine within 14 days prior to vaccination, or any live vaccine within 28 days prior to vaccination.\n* Prior receipt of any RSV vaccine.\n* Administration of immunoglobulin and\u002For any blood or plasma derivative (e.g., gamma globulin, intravenous immunoglobulin) within 3 months prior to vaccination, or planned administration during the study period.\n* Long-term use (consecutive use \\> 14 days) of immunosuppressive or other immunomodulatory agents within 3 months prior to vaccination or planned use during the study period. Systemic glucocorticoids ≥ 20 mg prednisone or equivalent daily for ≥ 14 days are considered long-term use. Topical preparations (ointments, eye drops, inhalations, nasal sprays) at doses not exceeding those recommended in the package insert are permitted.\n* Use of long-acting immunomodulatory agents (e.g., infliximab) within 6 months prior to vaccination or planned use during the study period.\n* History of chronic alcohol abuse and\u002For drug abuse that, in the investigator's judgment, may interfere with study assessments.\n* Planned migration during the study period that would preclude completion of all study procedures.\n* Any other condition that, in the investigator's judgment, may interfere with the validity of study evaluations, with special attention to respiratory infection symptoms.",true,"ALL","20 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T cell memory formation.",[26],"Respiratory Syncytial Virus (RSV)","NOT_YET_RECRUITING","2026-05-25",{"date":30,"type":31},"2026-06-01","ACTUAL",{"date":33,"type":20},"2026-06-02",{"date":35,"type":20},"2028-08-31",{"name":37,"class":38},"MAXVAX Biotechnology Limited Liability Company","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100630825","phase-1-safety-tolerability-and-immunogenicity-of-a-maternal-respiratory-syncytial-virus-rsv-vaccine-mkk900-in-healthy-adult-women-100630825","NCT07492706","Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women","A Phase 1, Randomized, Blinded, Active Controlled Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant, Stabilized Pre-F Respiratory Syncytial Virus (RSV) Vaccine (MKK900), Non-adjuvanted, in Healthy Women Aged 18-49 Years","RSVVaccine","Inclusion Criteria:\n\n1. Adult females 18-49 years old on the day of vaccination.\n2. Generally healthy, as established by medical history and clinical examination before vaccination and absence of unresolved acute disease or acute exacerbation of chronic disease.\n3. Intent to reside in the area of the study site for the throughout the study visits and also available for phone follow ups after vaccination.\n4. Signing an Informed Consent Form indicating that the purpose, procedures and potential risks and benefits of the study have been explained including an opportunity to ask questions.\n5. Females must not be of childbearing potential OR those who are of childbearing potential must be non-pregnant and non-lactating and willing to use acceptable, highly effective methods of contraception from 28 days prior to vaccination on Day -1 through to 90 days after vaccination. Females must also agree not to donate ova from the first dose of the study vaccine until at least 90 days after vaccination.\n\nExclusion Criteria:\n\n1. Recent RSV exposure\u002Fvaccination: History of RSV infection within 6 months or prior RSV vaccination.\n2. Pregnancy\u002Flactation: Pregnant, breastfeeding, or planning pregnancy within 90 days post-vaccination.\n3. Recent investigational products: Received any investigational product within 30 days or plans study participation during this trial.\n4. Recent vaccines: Live vaccine within 30 days or any other vaccine within 14 days before study vaccination, or planned vaccination within 3 months after.\n5. Blood products: Received immunoglobulins or blood products within 6 months.\n6. Recent blood donation: Donation\u002Floss of \\>450 mL of blood or components within 14 days of Day 1.\n7. Active illness: Acute illness or acute flare of chronic disease within 3 days before vaccination.\n8. Vaccine allergies: Allergy to vaccine components (especially aminoglycosides) or severe reactions to past vaccines.\n9. Neurological conditions: History of seizures, epilepsy, encephalopathy, or significant neurological disorders.\n10. Mental health concerns: Any mental illness that may affect study compliance or AE reporting.\n11. Malignancy: Active cancer or cancer within past 5 years (except adequately treated skin or cervical lesions).\n12. Splenic issues: Asplenia, functional asplenia, or splenectomy.\n13. Immunodeficiency\u002Fautoimmune disease: Congenital\u002Facquired immunodeficiency or autoimmune diseases per Investigator judgement.\n14. Immunosuppressive therapy: Systemic immunosuppressants (e.g., prolonged steroids) within 3 months; inhaled\u002Ftopical steroids allowed.\n15. Severe chronic diseases: Severe cardiac, pulmonary, hepatic, renal disease, or diabetes.\n16. Coagulation issues: History of thrombocytopenia or bleeding disorders contraindicating IM injection.\n17. Fever\u002Finfection: Fever \\>38°C or active systemic infection within 7 days of vaccination.\n18. Hypertension: Abnormal or uncontrolled high blood pressure at screening (≥140\u002F90 mmHg).\n19. Known or suspected infection with HBV, HCV, or HIV.\n20. Alcohol or drug abuse, including regular alcohol intake of \\>14 drinks\u002Fweek or \\>4 drinks\u002Fday.\n21. Positive drug screen (amphetamines, barbiturates, benzodiazepines, cocaine, THC, methadone, methamphetamine, opiates, PCP, tricyclic antidepressants) or positive alcohol breath test at Screening or Day -1.\n22. Inability to assess injection site due to tattoos or skin conditions on both deltoids.\n23. Study site employees involved in the protocol or with access to study data.\n24. Any other condition that may impact participant safety or interfere with study assessments, as judged by the Investigator.","FEMALE","18 Years","49 Years",{"count":51,"type":20},120,[53],"PHASE1","A Phase 1 study to evaluate safety, tolerability and immunogenicity a RSV vaccine in healthy women 18 to 49 years of age",[26],"2026-03-19",{"date":58,"type":31},"2026-03-25",{"date":60,"type":20},"2026-04-01",{"date":62,"type":20},"2027-01-15",{"name":37,"class":38},2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":15,"sex":16,"minAge":72,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100613887","phase-3-phase-iii-clinical-trial-of-the-recombinant-respiratory-syncytial-virus-vaccine--cho-cell-100613887","NCT07272434","Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 60 Aears and Above","Inclusion Criteria:\n\n1. A male or female can provide legal identification at the time of enrollment, and is 60 years of age or older (women are required to be infertile).\n\n   (Note: Women with infertility include those who have been menopausal or have undergone sterilization (including hysterectomy, bilateral salpingectomy, bilateral oophorectomy, etc.)\n2. Be able to understand the trial procedures, risks and benefits and voluntarily agree to participate in the study and sign an informed consent.\n3. Be able to participate in all scheduled visits and comply with the protocol requirements\n4. Participants with stable health conditions considered by the investigator. Stable health conditions refer to patients with chronic diseases whose conditions are stable (regardless of whether they have received specific treatment or not), such as diabetes, hypertension, chronic obstructive pulmonary disease, asthma, etc. If the researcher determines that the condition is stable, they may be allowed to participate in this trial.\n\nExclusion Criteria:\n\nParticipants who meet any of the following exclusion criteria will not be allowed to enter the study (if the number of participants is not yet met, if the criteria described in \"\\*\" are met during screening, repeated screening may be performed)\n\n1. \\*Axillary temperature\\>37.3℃.\n2. History of RSV infection within 6 months before enrollment.\n3. \\*New onsets of respiratory tract infection symptoms like cough, sputum, shortness of breath, wheezing, fever, runny nose or nasal congestion within 7 days before enrollment.\n4. \\*Acute diseases or acute exacerbation of chronic disease within 3 days before vaccination.\n5. \\*Within 3 days before enrollment, antipyretic and analgesic drugs (except enteric-coated aspirin tablets for the prevention of cardiovascular and cerebrovascular diseases) and antihistamines were used\n6. Those who are allergic to the known components in the test vaccine \\[saponin (QS-21), dioleoyl phosphatidylcholine (DOPC), cholesterol, sucrose, sodium dihydrogen phosphate, anhydrous sodium dihydrogen phosphate, polysorbate 80, sodium chloride, hydrochloric acid and sodium hydroxide\\] Those who have a history of severe allergies after any vaccination or medication use \\[such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), severe urticaria, etc.\\] or serious adverse reactions.\n7. Asplenia or functional asplenia, and any condition leading to asplenia or splenectomy.\n8. Those who have had or are currently suffering from malignant tumors (except for clinically cured carcinoma in situ and papillary thyroid carcinoma).\n9. Patients are diagnosed with autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease and autoimmune thyroid disease.\n10. Persons with known or suspected immunodeficiency disorders \\[e.g. primary or secondary immunodeficiency, or diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus infection or immunosuppressive\u002Fcytotoxic agent therapy (e.g. cancer chemotherapy, organ transplantation or autoimmune disease treatment) resulting in confirmed or suspected immunosuppression or immunodeficiency\\].\n11. According to the investigator's assessment,there is any disease that may make intramuscular injections unsafe, such as a history of thrombocytopenia or other coagulation disorders.\n12. Those who have a history or are currently suffering from severe clinical diseases that have not been cured (such as severe cardiovascular and cerebrovascular diseases, liver and kidney diseases, respiratory system diseases, diabetes with complications, major surgeries, etc.) and may affect the evaluation of the trial.\n13. Those who have had or are currently suffering from thrombotic diseases.\n14. Patients with a history of untreated TB or active TB at enrollment.\n15. \\*Hypertension with poor medication control (on-site blood pressure measurement before vaccination: systolic blood pressure≥150mmHg and\u002For diastolic blood pressure≥100mmHg).\n16. Those with severe arrhythmias (such as atrial fibrillation).\n17. Those with a history or family history of convulsions, epilepsy, congenital brain hypoplasia, mental illness, etc., or a history of brain nerve tissue damage caused by other serious neurological diseases (such as brain tumors, cerebral hemorrhage, brain infections, chemical drug poisoning, etc.).\n18. Use of any experimental or unapproved product (drug, vaccine or medical device) other than the vaccine used in this trial or participate in other clinical trials within 30 days prior to enrollment or during the trial period.\n19. \\*Within 14 days prior to enrollment, any non-live vaccine has been administered, or within 28 days, a live vaccine or nucleic acid vaccine has been administered.\n20. Has received the RSV vaccine before.\n21. Use of immunoglobulin and\u002For any blood preparation or plasma derivative, such as gamma globulin or intravenous human immunoglobulin, within 3 months prior to enrollment or plan to use during the trial\n22. Within the 3 months prior to enrollment or if it is expected to be used for a long period during the trial (continuous for more than 14 days), immunosuppressive agents or other immunomodulatory drugs (such as long-term use of systemic glucocorticoids for ≥ 14 days, with a dose of ≥ 20mg\u002Fday prednisone or equivalent prednisone dose; local medications are allowed, such as ointments, eye drops, inhalants or nasal sprays, but the local medication dosage must not exceed the recommended dosage in the instructions)\n23. Long-acting immunomodulatory drugs (such as infliximab) were used within 6 months before enrollment or during the planned trial period.\n24. The researchers determined that the drinking behavior and\u002For drug abuse history that might affect the assessment of the trial (Note: within the last three months, men had an average of more than 14 standard drinks per week, and women had an average of more than 7 standard drinks per week; 1 standard drink contained 14g of alcohol, such as 360mL of beer or 45mL of 40% alcohol spirit or 150ml of wine.) Drug abuse refers to the repeated and excessive use of drugs with dependent characteristics or potential for dependence, which is not related to recognized medical needs and falls under non-medical purpose drug use.\n25. Planned move to a location that will prohibit participating in the trial until study end;\n26. Any condition that, in the opinion of the investigator, may affect the safety of the participant or the evaluation of the study results.","60 Years",{"count":74,"type":20},25000,[76],"PHASE3","This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.",[26],"RECRUITING","2025-11-26",{"date":82,"type":31},"2025-12-09",{"date":84,"type":31},"2025-10-22",{"date":86,"type":20},"2028-12-31",{"name":37,"class":38},8,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":15,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100566401","phase-3-phase-iii-clinical-trial-of-lot-to-lot-consistency-of-recombinant-herpes-zoster-vaccine-cho-cell-100566401","NCT06654700","Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).","A Randomized, Double-blind Phase III Clinical Trial to Evaluate the Lot-to-lot Consistency of Three Consecutive Batches of Recombinant Herpes Zoster Vaccine (CHO Cell) Produced At a Commercial Scale in Subjects Aged 40 Years and Older.","Inclusion Criteria:\n\n1. A male or female permanent resident aged 40 years and older at enrollment, with valid identity;\n2. Subjects voluntarily agree to participate in the study and signed an informed consent;\n3. Be able to understand clinical trials, participate in all scheduled visits and comply with the protocol requirements(e.g. completion of the diary cards\u002Fquestionnaires, return for follow-up visits, have regular contact to allow evaluation during the study);\n4. Women of childbearing potential plan to avoid pregnancy and are willing to use effective contraception(e.g. oral contraceptive pills, injectable progestogen, percutaneous contraceptive patches, implants of levonorgestrel, intrauterine device, female and male sterilization or abstinence) within 12 months after the last vaccination, and the uses of the rhythm method alone, withdrawal alone, and emergency contraception, are not acceptable.\n\nExclusion Criteria:\n\n1. Axillary temperature \\> 37.0°C on the day of vaccination or acute illness;\n2. Current or history of herpes zoster;\n3. Previous vaccination against varicella or herpes zoster (either registered product or participation in a previous vaccine study);\n4. Pregnant (urine pregnancy test was positive) or lactating female;\n5. Receipt of live vaccine within 28 days, or any other vaccine within 14 days prior to vaccination;\n6. Receipt of immunoglobulin or intravenous immunoglobulin during 3 months before vaccination, or planned receipt 1 month post the last vaccination;\n7. Acute diseases(such as acute upper respiratory tract infection with fever, cough, sore throat) or acute exacerbation of chronic disease within 3 days before vaccination;\n8. Receipt of antipyretic, analgesic and allergy drugs within 3 days before vaccination, except enteric-coated aspirin for cardiovascular diseases prevention;\n9. A known allergy to any components of the study vaccine, or history of severe allergy (e.g. Anaphylactic shock, allergic laryngeal edema, anaphylactoid purpura, thrombocytopenic purpura, Arthus reaction, severe urticaria) to any previous vaccination;\n10. Allergy to aminoglycoside antibiotics;\n11. History of convulsions, epilepsy, congenital brain dysplasia, mental illness or family history, or history of brain nerve tissue damage due to other severe neurological disorders(e.g. brain tumor, cerebral hemorrhage, cerebral infarction, brain infection disease, chemical drug poisoning);\n12. Asplenia or functional asplenia, or splenectomy caused by any condition;\n13. Primary or secondary impairment of immune function, diagnosed congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease or other autoimmune diseases;\n14. Receipt of Immunosuppressive therapy(such as long-term use of systemic glucocorticoid ≥14 days, ≥20mg\u002Fday prednisone or equivalent dose) or long-acting immune-modifying drugs(e.g. Infliximab) during the period starting 6 months before vaccination or planned administration 1 month after the last vaccination, but topical steroids(e.g. ointment, eye drops, inhalants, nasal sprays) that do not exceed the dosage recommended in the instructions or have any systemic signs are acceptable;\n15. Patients with severe chronic diseases, including but not limited to severe cardiovascular diseases (pulmonary heart disease, pulmonary edema), severe liver and kidney diseases, and diabetes mellitus with complications;\n16. History of thrombocytopenia or other coagulation disorders, which may cause intramuscular injection contraindications;\n17. Abnormal and uncontrolled blood pressure during physical examination before vaccination (for subjects aged 40-59: systolic pressure ≥ 140 mmHg and\u002For diastolic pressure ≥ 90 mmHg; for subjects aged ≥60, systolic pressure ≥ 150 mmHg and\u002For diastolic pressure ≥ 100 mmHg);\n18. History of drug abuse (narcotic drugs, psychotropic drugs);\n19. Patients with previous or current malignant tumors (except papillary thyroid cancer);\n20. Receipt of investigational or unapproved products (drugs or vaccines) within 6 months before vaccination; or planned participation in another clinical study during the study period;\n21. Any condition that, in the opinion the investigator, makes subjects ineligible for the study.","40 Years",{"count":98,"type":20},1200,[76],"To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.",[102],"Herpes Zoster","2024-11-18",{"date":105,"type":31},"2024-11-20",{"date":107,"type":20},"2024-12-09",{"date":109,"type":20},"2025-05-01",{"name":37,"class":38},1,""]